Noven Pharmaceuticals has appointed Patrick Gallagher as vice president (VP) of business development. Gallagher has more than 25 years experience in pharma and biotech at companies including Acusphere, Mylan Laboratories and Bristol-Myers Squibb.
Jeffrey Buchalter has resigned as CEO and director of Enzon. Buchalter will be replaced by a newly formed executive committee of the board consisting of Alex Denner, Richard Mulligan and Rolf Classon. The committee will act as CEO until an appointment is made.
Aton Pharma has named Wayne Mulcahy as VP, clinical operations. Mulcahy has more than 30 years experience in clinical operations and worked at companies including Teva, Barr and Alita Pharmaceuticals.
Stephen Davis has been appointed to the board of directors at AP Pharma. Davis was CEO of Neurogen, which was recently acquired by Ligand Pharmaceuticals, having joined the company in 1994.
Tarsa Therapeutics has added to its senior management team, appointing David Krause as chief medical officer and Thomas Wicks as VP, global regulatory affairs.
Krause joins Tarsa from Zelos Therapeutics and over a 20 year career he has also worked at Vicuron Pharmaceuticals and GlaxoSmithKline. Wicks has 25 years of regulatory strategic planning experience at companies including Sanofi, Purdue Pharma and Odyssey.
Michel Lagueux has resigned from his position as non-executive director at Akela Pharma. Lagueux has served on the board since May 2009.
Inspire Pharmaceuticals has appointed Adrian Adams as president and CEO. He has also been elected to the company’s board of directors. Adams was previously president and CEO of Sepracor and has also worked at Kos Pharmaceuticals, ICI and Novartis.